Cellular therapy products such as CAR-T show promising clinical efficacy in fighting cancer. But the accompanying risk of fast-onset cytokine release syndrome (CRS) has driven a standard of care that includes lengthy hospital stays following infusion. Long hospital stays—often 2 weeks—present a high risk for infection along with a high financial and emotional burden for...